• Explore /
  • Poster
  • / Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.

Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.

Abstract Poster

Authors

null

Peter H. O'Donnell

University of Chicago Comprehensive Cancer Center, Chicago, IL

Peter H. O'Donnell , Jonathan E. Rosenberg , Christopher J. Hoimes , Daniel P. Petrylak , Matthew I. Milowsky , Rana R. McKay , Sandy Srinivas , Terence W. Friedlander , Chethan Ramamurthy , Mehmet Asim Bilen , Earle F Burgess , Nataliya Mar , Helen Moon , Daniel M. Geynisman , Saby George , Anne-Sophie Carret , Yao Yu , Maria Guseva , Blanca Homet Moreno , Thomas W. Flaig

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03288545

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 499)

DOI

10.1200/JCO.2023.41.6_suppl.499

Abstract #

499

Poster Bd #

K3

Abstract Disclosures

Similar Posters

First Author: Nataliya Mar

First Author: Jonathan E. Rosenberg

First Author: Jonathan E. Rosenberg

First Author: Christopher J. Hoimes